About
Andrew Kruegel is a medicinal chemist and pharmacologist who has focused on drug design and preclinical development for psychiatric treatment. He has also developed expertise in business operations, fundraising, and intellectual property strategy.
Founder at Gilgamesh PharmaceuticalsYC S20
Intro paths
YC
Andrew went through Y Combinator (Summer 2020) — any YC alum in your network can reach them through the YC community.
GP
Their group partner at YC was Jared Friedman, YC Group Partner — the partner who ran Gilgamesh Pharmaceuticals's batch and knows the company first-hand. YC profile ↗
→
In turn, Andrew can intro founders to Gilgamesh Pharmaceuticals's investors below.
Gilgamesh Pharmaceuticals's investors · 11
Aera VCSingapore · $25K – $5M checksFrontera Technology VenturesTexasFrontier Path VCLondonJames Beshara FundLos AngelesJLSNew YorkMagnetic VenturesBoston · $1M – $6M checksNoeticTorontoPrime Movers LabJackson · $2M – $30M checks · since 2022PsyMed VenturesBerkeleyStrawberry Creek VenturesManchesterY CombinatorSan Francisco · $500K checks · since 2020
Co-founders at Gilgamesh Pharmaceuticals
JS
Jonathan SpornFounder
DS
Dalibor SamesFounder
JS
JONATHAN SPORNFounder
AK
Andrew Kruegel, Ph.D.Executive Officer
JS
Jonathan Sporn, M.D.President and Chief Executive Officer
Experience
- Gilgamesh PharmaChief Scientific Officercurrent2021 — presentNew York City Metropolitan Area
- Kures Inc.Chief Scientific Officer2017 — 2021New York, NY
- Columbia University in the City of New YorkAssociate Research Scientist2016 — 2019New York, NY
- Columbia University in the City of New YorkPostdoctoral Scientist2015 — 2016New York, NY
- Columbia University in the City of New YorkPhD Student2010 — 2015
- RocheIntern2009
Skills & more
Organic Synthesis20Drug Discovery20Laboratory12Chemistry16Medicinal Chemistry9Life Sciences6Research10Biochemistry5CNS disorders6Treatment of depression4Science9Drug Design3
+12 more
Growth FactorsData AnalysisMass SpectrometryMolecular ModelingHPLCNMRScientific ManagementScientific WritingTreatement of neurodegenerative disordersAnimal ModelsMolecular PharmacologyPre-Clinical DevelopmentLanguages English · minimal French
From Andrew's professional profile.
Frequently asked questions
- Who is Andrew Kruegel?
- Andrew Kruegel is a medicinal chemist and pharmacologist who has focused on drug design and preclinical development for psychiatric treatment. He has also developed expertise in business operations, fundraising, and intellectual property strategy.
- Where does Andrew Kruegel work?
- Andrew Kruegel is Founder of Gilgamesh Pharmaceuticals.
- What companies did Andrew Kruegel found?
- Andrew Kruegel founded Gilgamesh Pharmaceuticals.
- Where did Andrew Kruegel go to school?
- Andrew Kruegel studied at Columbia University (Doctor of Philosophy (Ph.D.), Organic Chemistry); Stevens Institute of Technology (Bachelor of Science (BS), Chemistry).
Founder mafias
Y Combinator mafia8,773
Also came through, then founded or led a company.
Sam AltmanPresidentFounded Tools for Humanity +3Jessica LivingstonCo-founderFounded Y CombinatorAlexis OhanianYC Summer 2005Founded RedditFred EhrsamYC Summer 2012Founded Nudge +1Matt HuangYC Winter 2011Founded HotspotsTrae StephensYC Winter 2022Founded Pursuit +1
+ 8,766 more
Columbia University mafia200
Also came through, then founded or led a company.
Ben HorowitzBAFounded OpswareChris DixonBachelor of Arts - BAFounded HunchKai-Fu LeeA.B.Founded 01Robin ChanB.A.Founded Operator +2Kevin M. SlawinB.A.Founded Perseus SENOLYTIX +2Joey LevyBachelor of Arts (B.A.)Founded Draftpot +2
+ 193 more
Stevens Institute of Technology mafia12
Also came through, then founded or led a company.
Douglas E. RogersBEFounded DubPrime +1Al SistoBachelor of EngineeringFounded Phoenix TechnologiesBill BarhydtBachelor of ScienceFounded AbraRahul MahidaChemical-BiologyFounded DaivergentMark RothBEFounded Connected LivingMykel PereiraComputer ScienceFounded Haywheel
+ 5 more
Gilgamesh Pharma mafia2
Also came through, then founded or led a company.
Same school
Also attended Columbia University726
Ben HorowitzCo-founder & General Partner at Andreessen HorowitzDoug LeonePartner at Sequoia Capital; former Global Managing PartnerChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzKai-Fu LeeChairman of Sinovation Ventures and CEO of 01.AIGabriella GiglioHR & Executive Talent at General CatalystScott BillerInvestor at GV (Google Ventures)
+ 720 more
Also attended Stevens Institute of Technology24
Srinivas RaoInvestor at Phoenix Venture PartnersDaniella KranjacInvestor at Avant BioLindsay GoeddelInvestor at Constellation Technology VenturesNikos VogiatzisPartner at Corallia VenturesMiriam Moreno-HerediaOperations Associate at Accial CapitalGarry TurkingtonInvestor at CapitalT
+ 18 more
Shared employers
Also worked at Gilgamesh Pharma6
Also worked at Columbia University in the City of New York174
Reid HoffmanCo-founder of LinkedIn; Partner at GreylockRon ZoriVenture Partner at Lerer HippeauRalph DeBernardoPartner, Investor Relations at Sapphire VenturesRichard ChesworthInvestor at Third Rock VenturesJesse Coors-BlankenshipCo-founder, General Partner at Parkway Venture CapitalLauren YoungHead of Platform at AlleyCorp
+ 168 more
Also worked at Roche95
Joe HorsmanInvestor at Madrona Venture GroupMarco PrunottoInvestor at MedicxiMike FitzgeraldInvestor at High AlphaUri LopatinInvestor at Khosla VenturesJan-Olivier FillolsSenior Managing Director at Marlin Equity PartnersNarges BaniasadiVenture Partner at Think+ Ventures Management, Llc
+ 89 more